WO2019013569A1 - 활성형 d-프롤린 리덕타제를 발현하는 미생물 및 활성형 d-프롤린 리덕타제를 생산하는 방법 - Google Patents
활성형 d-프롤린 리덕타제를 발현하는 미생물 및 활성형 d-프롤린 리덕타제를 생산하는 방법 Download PDFInfo
- Publication number
- WO2019013569A1 WO2019013569A1 PCT/KR2018/007914 KR2018007914W WO2019013569A1 WO 2019013569 A1 WO2019013569 A1 WO 2019013569A1 KR 2018007914 W KR2018007914 W KR 2018007914W WO 2019013569 A1 WO2019013569 A1 WO 2019013569A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- prda
- proline
- reductase
- prdh
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y121/00—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
- C12Y121/04—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with a disulfide as acceptor (1.21.4)
- C12Y121/04001—D-Proline reductase (dithiol) (1.21.4.1)
Definitions
- the present invention relates to a method for producing a D-proline reductase-expressing microorganism and an active D-proline reductase thereof, wherein the activity of PrdA protein, PrdB protein and PrdH protein is enhanced. Based on this, a method of reducing D-proline and D-proline-like substances, and a method of simultaneously expressing Prd protein and PrdB protein and having an activity of converting an inactive D-proline reductase to an active D-prolyl reductase Lt; / RTI > protein.
- 5-aminovaleric acid is a monomer of nylon 5, which is known to be converted from proline by the D-proline reductase.
- a pyrroleyl group in order to activate the D-proline reductase, a pyrroleyl group must be introduced simultaneously with the precise self-cleavage of the PrdA protein.
- this is regarded as a technical limitation, and a demand for a method capable of producing an active D-proline reductase is increasing.
- the present inventors have continuously studied for the development of recombinant expression systems and strains capable of producing D-proline reductase (D-rpoline reductase) in an active form, and have conducted studies on applicability to various D-proline-like substrates. From this, we first identified the PrdH protein, which was co-expressed with the PrdA protein and the PrdB protein, converting the inactive D-rpoline reductase into the active D-prolyl reductase. In addition, the activity of the microorganisms expressing the active D-proline reductase and the D-proline reductase produced therefrom has been successfully demonstrated.
- One object of the present application is to provide a microorganism expressing an active D-proline reductase, wherein the activity of PrdA protein, PrdB protein and PrdH protein is enhanced.
- Another object of the present invention is to provide a method for producing an active D-proline reductase comprising culturing the microorganism in a medium, and recovering the active D-proline reductase from the microorganism or medium .
- Another object of the present invention is to provide a method for producing 5-aminovaleric acid (5-AVA), gamma -aminobutyric acid (5-aminobutyric acid), and aminobutyric acid (5-aminobutyric acid) using an active D-proline reductase produced by the microorganism or the microorganism.
- GABA 5-aminovaleric acid
- gamma -aminobutyric acid gamma -aminobutyric acid
- aminobutyric acid aminobutyric acid
- the present invention also provides a method for producing at least one selected from the group consisting of 5-amino-4-hydroxypentanoic acid.
- Another object of the present application is to provide a PrdH protein that is co-expressed with the PrdA protein and PrdB to convert an inactive D-proline reductase to an active D-prolyl reductase.
- Another object comprises the step of transforming an expression cassette comprising, prdB or prdB and prdH gene transformed with an expression cassette comprising a prdA or prdA and prdH gene into a host cell in a host cell, And a method for producing a microorganism expressing an active D-proline reductase.
- the present application newly proposed a polypeptide capable of converting an inactive D-prolinyl reductase into an active D-prolyl reductase, and interacts with a complex of PrdA and PrdB constituting the existing D-proline reductase, , Or the Prd operon to increase the activity of the active D-proline reductase to provide a novel active D-proline reductase, thereby providing a method of converting D-proline or an analogue thereof.
- FIG. 4 shows Western blot analysis results according to the expression of PrdB protein.
- FIG. 5 is a Western blot analysis result on the self-cleavage of the PrdA protein by the PrdH protein.
- FIG. 11 shows the results of TLC analysis evaluating the ability to convert D-proline-like substances through the active D-proline reductase.
- active D-prolinyl reductase in the present application means that, among the PrdA protein and PrdB protein constituting D-proline ritratase, the PrdA protein is precisely cleaved by PrdH, Refers to a protein complex consisting of alpha-PrdA, beta-PrdA, and PrdB proteins separated by -PrdA and beta-PrdA, wherein the pyloyl group is bonded to the amino terminal of the double-separated alpha-PrdA moiety.
- PrdA protein is a component of the protein complex of D-proline reductase.
- the PrdA protein is an alpha-PrdA protein (carboxyl terminal fragment) and a beta-PrdA protein (Amino terminal fragment).
- alpha-PrdA protein carboxyl terminal fragment
- beta-PrdA protein Amino terminal fragment
- the PrdA protein self-cleavage process is characterized by the introduction of a pyruvoyl group at the amino terminus of the alpha-PrdA protein at the same time as the cleavage of the peptide bond .
- the pylorbyl group is known to be an essential residue for the activity of D-proline reductase, because it acts to lower the activation energy of the substrate (Kabisch et al., J. Biol. Chem., 1999, 274 (13), 8445 -8454).
- the pivalobyl group is not introduced into the protein cleavage mechanism through a general hydrolysis reaction, various studies have been conducted to solve this problem.
- the PrdA protein fragment from which the amino-terminal was removed was subjected to artificial cleavage by inducing the addition of a reducing agent such as NaBH 4 Has progressed.
- polynucleotides having homology or identity can be detected using hybridization conditions that include a hybridization step at a Tm value of 55 ° C and using the conditions described above.
- the Tm value may be 60 ° C, 63 ° C, or 65 ° C, but is not limited thereto and may be suitably adjusted by those skilled in the art according to the purpose.
- pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vector and the like can be used but are not limited thereto.
- the vector usable in the present application is not particularly limited, and known expression vectors can be used.
- a polynucleotide encoding a target protein can be inserted into a chromosome through a vector for intracellular chromosome insertion.
- the insertion of the polynucleotide into the chromosome can be accomplished by any method known in the art, for example, homologous recombination, but is not limited thereto. And may further include a selection marker for confirming whether or not the chromosome is inserted.
- the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a gene construct containing all the elements necessary for its expression.
- the expression cassette can typically include a promoter operably linked to the polynucleotide, a transcription termination signal, a ribosome binding site, and a translation termination signal.
- various factors that can help the efficient production of the target protein can be included inside or outside the expression cassette.
- the expression cassette may be in the form of an expression vector capable of self-replication.
- the polynucleotide may be introduced into the host cell in its own form and operatively linked to the sequence necessary for expression in the host cell, but is not limited thereto.
- one specific example of the present application is a microorganism expressing an active D-prolyl reductase having enhanced activity of PrdA protein, PrdB protein and PrdH protein, in addition to a microorganism expressing at least one of PrdC, PrdG, or PrdF And a microorganism expressing an active D-proline reductase, wherein the activity of the protein is enhanced.
- PrdD, PrdE, and PrdE 2 protein has the PrdA protein with high sequence homology or identity.
- PrdD protein shows high homology or identity with beta-PrdA protein
- PrdE and PrdE 2 proteins show high homology or identity with alpha-PrdA protein.
- the PrdD, PrdE, and PrdE 2 protein can be obtained from the GenBank sequences of the known database NCBI.
- PrdD, PrdE, and PrdE 2 proteins pepto Clostridium difficile silane 630 (pepto Clostridium difficile Silicate 630 (Clostridium difficile 630)) derived PrdD, PrdE, and PrdE 2 protein, in particular SEQ ID NO: 7, 9 , 11, or a protein having an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO: 8, 10, or 12, but is not limited thereto.
- Escherichia Escherichia
- Escherichia An air Winiah (Erwinia) genus
- Serratia marcescens Serratia marcescens
- Providencia Providencia
- Corynebacterium Corynebacterium
- Brevibacterium Brevibacterium Microbial strains belonging to the genus Escherichia, and examples of Escherichia genus include, but are not limited to, Escherichia coli.
- the Escherichia genus microorganism producing the active D-proline reductase capable of expressing the polypeptide having the D-proline reductase activity of the present application can be obtained by expressing the polypeptide by various known methods in addition to the introduction of the vector It can contain all microorganisms.
- cultivation means that the microorganism is grown under moderately controlled environmental conditions.
- the culturing process of the present invention can be carried out according to a suitable culture medium and culture conditions known in the art. Such a culturing process can be easily adjusted by those skilled in the art depending on the strain to be selected.
- the step of culturing the microorganism is not particularly limited, but can be carried out by a known batch culture method, a continuous culture method, a fed-batch culture method and the like.
- the culturing conditions are not particularly limited, but may be carried out at a suitable pH (for example, a pH of 5 to 9, specifically, a pH of 5 to 10, and a pH of 5 to 10) using a basic compound such as sodium hydroxide, potassium hydroxide or ammonia or an acidic compound such as phosphoric acid or sulfuric acid. PH 6 to 8, most specifically pH 6.8).
- a suitable pH for example, a pH of 5 to 9, specifically, a pH of 5 to 10, and a pH of 5 to 10
- a suitable pH for example, a pH of 5 to 9, specifically, a pH of 5 to 10, and a pH of 5 to 10
- a basic compound such as sodium hydroxide, potassium hydroxide or ammonia or an acidic compound such as phosphoric acid or sulfuric acid.
- PH 6 to 8 most specifically pH 6.8
- defoaming agents such as fatty acid polyglycol esters can be used to inhibit the formation of bubbles.
- oxygen or oxygen-containing gas is injected into
- cultured E. coli transformed with pETDuet_H6-prdA-H6 vector was cultured with or without D-proline (10 mM) as a substrate.
- selC gene and pCDFDuet_prdB-H6 vector constructed above were separated by agarose gel after XbaI restriction enzyme treatment, and finally, pCDFDuet_prdB-H6_P selC -selC vector was constructed through T4 ligase reaction.
- PrdA protein expression vector pETDuet_H6-prdA-H6
- PrdB protein expression vector pCDFDuet_prdB-H6-P selC _selC and pACYCDuet_selA_selB vector combinations.
- the above three expression vectors were transformed into E. coli BL21 (DE3) and cultured in LB medium (50 ml) containing antibiotics (ampicillin 0.1 mg / ml, spectinomycin 50 ⁇ g / ml, chloramphenicol 30 ⁇ g / ml) (37 ° C, 200 rpm).
- PrdA PrdH and co-expression vector pETDuet_prdH_H6-prdA-H6
- PrdB protein expression vector pCDFDuet_prdB-H6-P selC _selC and pACYCDuet_selA_selB vector combinations.
- the culture was carried out in the same manner as in 1).
- LsPrdA protein and the LsPrdB (U151C) protein were coexpressed, the non-cleaved form of the LsPrdA protein (Pro-LsPrdA protein) and the LsPrdB protein were expressed, and at the same time, the non-specific degradation phenomenon of the LsPrdA protein was confirmed lane1).
- Pro-LsPrdA protein was decreased and additional protein band was confirmed.
- LsPrdA protein self-cleavage was confirmed (FIG. 7, lane 2).
- the LsPrdH protein has about 55% amino acid sequence homology with the established PrdH protein, but has the same property that it is encoded in the genomic structure by the gene ORF located between the prdA gene and the prdB gene.
- PrdH and LsPrdH proteins which have relatively low level of sequence homology but exist at similar positions in the genome structure, are the same, and the active D -
- PrdH and LsPrdH proteins which have relatively low level of sequence homology but exist at similar positions in the genome structure, are the same, and the active D -
- PrdH and LsPrdH proteins which have relatively low level of sequence homology but exist at similar positions in the genome structure
- PrdD protein (amino acid sequence: Q17ZY7, UniProtKB, SEQ ID NO: 7 / nucleotide sequence: CD630_32400, NCBI GeneBank AM180355.1, SEQ ID NO: 8) derived from Peptococcal tritium difficilia 630 (Clostridium difficile 630) SEQ ID NO: Q17ZY2, UniProtKB, SEQ ID NO: 9 / base sequence: CD630_32390, NCBI GeneBank AM180355.1, SEQ ID NO: 10), and PrdE 2 protein (amino acid sequence: Q17ZY3, UniProtKB, SEQ ID NO: 11 / base sequence: CD630_32380, NCBI GeneBank AM180355 1, SEQ ID NO: 12) were added to the ribosome binding site between the genes so that they could be expressed simultaneously with the PrdA protein.
- PrdG protein is presumed to be membrane protein, but no precise function has been reported to date.
- PrdG protein (Amino acid sequence: Q17ZY0, UniProtKB, SEQ ID NO: 15 / nucleotide sequence: CD630_32360, NCBI GeneBank AM180355.1, which is not named PrdG protein in the sequence database) and PrdG protein
- SEQ ID NO: 16 The nucleotide sequence of PrdG protein (SEQ ID NO: 16) based on the homology of C. sticklandii PrdG protein was synthesized using NcoI / NotI restriction endonuclease sequence at amino terminus and carboxyl terminus, respectively.
- the three kinds of expression vectors were transformed into E. coli BL21 (DE3) and cultured in LB medium containing antibiotics (ampicillin 0.1 mg / ml, spectinomycin 50 ⁇ g / ml, chloramphenicol 30 ⁇ g / ml) Deg.] C, 200 rpm).
- antibiotics ampicillin 0.1 mg / ml, spectinomycin 50 ⁇ g / ml, chloramphenicol 30 ⁇ g / ml
- 0.1 mM IPTG was added when the OD600 value reached 0.5-0.6, 10 ⁇ M sodium selenite was added, and then 16 hours was further cultured.
- the obtained E. coli cells were subjected to centrifugation after correcting the final OD to 50, and then washed with 1 ml of 0.1 M phosphate buffer (pH 8.0) after the first washing.
- D-proline a substrate for the D-proline reductase
- the metabolic pathway is designed to convert L-proline to D-proline and utilize it.
- proline racemase having proline isomer forming ability must be present at the same time.
- PrdA PrdH and protein expression vector pETDuet_prdH_prdA
- PrdBCG pCDFDuet_prdG_prdB-P selC _selC and pACYCDuet_selA-prdC_selB vector
- PrdA PrdH and protein expression vector pETDuet_prdH_prdA
- PrdBCGF protein expression vector P-pCDFDuet_prdGF_prdB selC _selC and pACYCDuet_selA- prdC_selB vector.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
서열번호 | 프라이머 | 서열(5'-3') |
25 | PrdA(C421A)-F | GGTATCCATGCATTAACTGCCATAGGACCTGCATC AAAAG |
26 | PrdA(C421A)-R | CTTTTGATGCAGGTCCTATGGCAGTTAATGCAT GGA TAC C |
Claims (24)
- PrdA 단백질, PrdB 단백질 및 PrdH 단백질의 활성이 강화된, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 PrdA 단백질은 서열번호 3 또는 서열번호 19의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 PrdB 단백질은 서열번호 5 또는 서열번호 21의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 PrdH 단백질은 PrdA단백질 및 PrdB단백질를 코딩하는 유전자 사이에 존재하는 유전자 ORF로부터 코딩된 단백질인, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 PrdH 단백질은 서열번호 1 또는 서열번호 23의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 추가적으로 PrdD, PrdE 및 PrdE2로 이루어진 군에서 선택되는 하나 이상의 단백질의 활성이 강화된, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 추가적으로 PrdC, PrdG 및 PrdF로 이루어진 군에서 선택되는 하나이상의 단백질의 활성이 강화된, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 미생물은 에스케리키아속 미생물인, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항에 있어서, 상기 미생물은 대장균인, 활성형 D-프롤린 리덕타제를 발현하는 미생물.
- 제1항 내지 제9항 중 어느 한 항의 미생물을 배지에서 배양하는 단계; 및상기 미생물 또는 배지로부터 활성형 D-프롤린 리덕타제를 회수하는 단계;를 포함하는 활성형 D-프롤린 리덕타제를 생산하는 방법.
- 제1항 내지 제9항 중 어느 한 항의 미생물 또는 제1항 내지 제8항 중 어느 한 항의 미생물이 생산하는 프롤린 리덕타제를 이용하여 아미노발레릭산(5-aminovaleric acid, 5-AVA), γ-아미노부티릭산(γ-aminobutyric acid, GABA) 및 5-아미노-4-하이드록시펜타노익산 (5-amino-4-hydroxypentanoic acid)로 이루어진 군에서 선택되는 하나 이상을 생산하는 방법.
- PrdA 단백질 및 PrdB 단백질과 동시 발현되어, 비활성형 D-프롤린 리덕타제를 활성형 D-프롤린 리덕타제로 전환시키는 활성을 갖는 PrdH 단백질.
- 제12항에 있어서, 상기 PrdA 단백질은 서열번호 3 또는 서열번호 19의 아미노산 서열을 포함하는, PrdH 단백질.
- 제12항에 있어서, 상기 PrdB 단백질은 서열번호 5 또는 서열번호 21의 아미노산 서열을 포함하는, PrdH 단백질.
- 제12항에 있어서, 상기 PrdH 단백질은 서열번호 1 또는 서열번호 23의 아미노산 서열을 포함하는, PrdH 단백질.
- prdA 또는 prdA와 prdH 유전자를 포함하는 발현카세트를 숙주세포에 형질전환하는 단계; 및prdB 또는 prdB와 prdH 유전자를 포함하는 발현카세트를 숙주세포에 형질전환하는 단계;를 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 PrdA 단백질은 서열번호 3 또는 서열번호 19의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 PrdB 단백질은 서열번호 5 또는 서열번호 21의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 PrdH 단백질은 PrdA단백질 및 PrdB단백질를 코딩하는 유전자 사이에 존재하는 유전자 ORF로부터 코딩된 단백질인, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 PrdH 단백질은 서열번호 1 또는 서열번호 23의 아미노산 서열을 포함하는, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 추가적으로 PrdD, PrdE 및 PrdE2로 이루어진 군에서 선택되는 하나 이상의 단백질의 활성이 강화된, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 추가적으로 PrdC, PrdG 및 PrdF로 이루어진 군에서 선택되는 하나 이상의 단백질의 활성이 강화된, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 미생물은 에스케리키아속 미생물인, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
- 제16항에 있어서, 상기 미생물은 대장균인, 활성형 D-프롤린 리덕타제를 발현하는 미생물을 제조하는 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18832792.8A EP3653715A4 (en) | 2017-07-12 | 2018-07-12 | ACTIVE D-PROLIN REDUCTASE EXPRESSING MICROORGANISMS AND METHOD FOR PRODUCING ACTIVE D-PROLIN REDUCTASE |
BR112020000525-8A BR112020000525A2 (pt) | 2017-07-12 | 2018-07-12 | micro-organismo que expressa d-prolina redutase ativa, métodos para produzir d-prolina redutase ativa e um ou mais ácidos, proteína prdh, e, método para produzir um micro-organismo que expressa d-prolina redutase ativa. |
CN201880046286.3A CN111032874A (zh) | 2017-07-12 | 2018-07-12 | 表达活性d-脯氨酸还原酶的微生物以及生产活性d-脯氨酸还原酶的方法 |
JP2020520419A JP7162660B2 (ja) | 2017-07-12 | 2018-07-12 | 活性型d-プロリンレダクターゼを発現する微生物及び活性型d-プロリンレダクターゼを生産する方法 |
US16/629,435 US11708564B2 (en) | 2017-07-12 | 2018-07-12 | Microorganism expressing active D-proline reductase and method of producing active D-proline reductase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0088632 | 2017-07-12 | ||
KR1020170088632A KR101951557B1 (ko) | 2017-07-12 | 2017-07-12 | 활성형 d-프롤린 리덕타제를 발현하는 미생물 및 활성형 d-프롤린 리덕타제를 생산하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019013569A1 true WO2019013569A1 (ko) | 2019-01-17 |
Family
ID=65001431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/007914 WO2019013569A1 (ko) | 2017-07-12 | 2018-07-12 | 활성형 d-프롤린 리덕타제를 발현하는 미생물 및 활성형 d-프롤린 리덕타제를 생산하는 방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11708564B2 (ko) |
EP (1) | EP3653715A4 (ko) |
JP (1) | JP7162660B2 (ko) |
KR (1) | KR101951557B1 (ko) |
CN (1) | CN111032874A (ko) |
BR (1) | BR112020000525A2 (ko) |
WO (1) | WO2019013569A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114854728B (zh) * | 2022-05-12 | 2023-11-24 | 云南师范大学 | 一种脯氨酸消旋酶及其制备和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150029526A (ko) | 2013-09-10 | 2015-03-18 | 광운대학교 산학협력단 | 라이신으로부터의 6-아미노헥사노산 또는 카프로락탐의 제조방법 |
-
2017
- 2017-07-12 KR KR1020170088632A patent/KR101951557B1/ko active IP Right Grant
-
2018
- 2018-07-12 WO PCT/KR2018/007914 patent/WO2019013569A1/ko unknown
- 2018-07-12 US US16/629,435 patent/US11708564B2/en active Active
- 2018-07-12 EP EP18832792.8A patent/EP3653715A4/en active Pending
- 2018-07-12 BR BR112020000525-8A patent/BR112020000525A2/pt active Search and Examination
- 2018-07-12 CN CN201880046286.3A patent/CN111032874A/zh active Pending
- 2018-07-12 JP JP2020520419A patent/JP7162660B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150029526A (ko) | 2013-09-10 | 2015-03-18 | 광운대학교 산학협력단 | 라이신으로부터의 6-아미노헥사노산 또는 카프로락탐의 제조방법 |
Non-Patent Citations (32)
Title |
---|
"Atlas Of Protein Sequence And Structure", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358 |
"Guide to Huge Computers", 1994, ACADEMIC PRESS |
"NCBI GenBank", Database accession no. FP565809.1 |
"NCBI GeneBank", Database accession no. AEBA01000066.1 |
ATSCHUL, [S.] [F., J MOLEC BIOL, vol. 215, 1990, pages 403 |
BEDNARSKI ET AL., EUR. J. BIOCHEM., vol. 268, 2001, pages 3538 - 3544 |
BOUILLAUT ET AL., J. BACTERIOL., vol. 195, no. 4, 2013, pages 844 - 854 |
CARILLO, SIAM J APPLIED MATH, vol. 48, 1988, pages 1073 |
DATABASE GenBank [O] PROTEIN; 12 May 2017 (2017-05-12), XP055571740, Database accession no. OTF89550.1 * |
DATABASE GenBank [O] PROTEIN; 14 April 2017 (2017-04-14), XP055571733, Database accession no. WP-003422102.1 * |
DATABASE GenBank [O] PROTEIN; 19 September 2015 (2015-09-19), XP055571751, Database accession no. WP-003702865.1 * |
DATABASE GenBank [O] PROTEIN; 27 February 2015 (2015-02-27), XP055571756, Database accession no. CBE 06920.1 * |
DATABASE GenBank [O] PROTEIN; 27 October 2016 (2016-10-27), XP055571744, Database accession no. WP-003422104.1 * |
DATABASE GenBank [O] PROTEIN; 30 March 2017 (2017-03-30), XP055571761, Database accession no. WP-080550217.1 * |
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 |
FONKNECHTEN ET AL., BMC GENOMICS, vol. 11, 2010, pages 555 |
FONKNECHTEN, N. ET AL.: "Clostridium Sticklandii, a Specialist in Amino Acid Degradation: Revisiting Its Metabolism through Its Genome Sequence", BMC GENOMICS, vol. 11, no. 1, 2010, pages 1 - 12, XP021072852 * |
GRIBSKOV ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 6745 |
ITOH ET AL., SCIENCE, vol. 340, no. 6128, 2013, pages 75 - 78 |
JACKSON ET AL., J. BACTERIOL., vol. 188, 2006, pages 8487 - 8495 |
JACKSON, S. ET AL.: "Analysis of Proline Reduction in the Nosocomial Pathogen Clostridium Difficile", JOURNAL OF BACTERIOLOGY, vol. 188, no. 24, December 2006 (2006-12-01), pages 8487 - 8495, XP055571767 * |
KABISCH ET AL., J. BIOL. CHEM., vol. 274, no. 13, 1999, pages 8445 - 8454 |
KABISCH, U. C. ET AL.: "Identification ofD-proline Reductase from Clostridium Sticklandii as a Seienoenzyme and Indications for a Catalytically Active Pyruvoyl Group Derived from a Cysteine Residue by Cleavage of a Proprotein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 13, 1999, pages 8445 - 8454, XP055571729 * |
NEEDLEMAN ET AL., J MOL BIOL., vol. 48, 1970, pages 443 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET., vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2 |
RUDNICK ET AL., BIOCHEMISTRY, vol. 14, no. 20, 1975, pages 4515 - 4522 |
See also references of EP3653715A4 |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
SU ET AL., NUCLEIC ACIDS RES., vol. 33, no. 8, 2005, pages 2486 - 2492 |
WU, X. ET AL.: "The Clostridium Difficile Proline Racemase Is not Essential for Early Logarithmic Growth and Infection", CANADIAN JOURNAL OF MICROBIOLOGY, vol. 60, no. 4, 2014, pages 251 - 254, XP055571774 * |
Also Published As
Publication number | Publication date |
---|---|
KR20190007571A (ko) | 2019-01-23 |
US20210317419A1 (en) | 2021-10-14 |
JP2020525045A (ja) | 2020-08-27 |
CN111032874A (zh) | 2020-04-17 |
BR112020000525A2 (pt) | 2020-07-21 |
EP3653715A1 (en) | 2020-05-20 |
US11708564B2 (en) | 2023-07-25 |
EP3653715A4 (en) | 2021-03-31 |
KR101951557B1 (ko) | 2019-02-22 |
JP7162660B2 (ja) | 2022-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015199396A1 (ko) | O-아세틸 호모세린을 생산하는 미생물 및 상기 미생물을 이용하여 o-아세틸 호모세린을 생산하는 방법 | |
WO2012087039A2 (ko) | 호모세린 아세틸 트랜스퍼라제 활성을 가지는 변이형 폴리펩티드 및 이를 발현하는 미생물 | |
WO2021125896A1 (ko) | 내막 단백질의 변이체 및 이를 이용한 목적 산물 생산 방법 | |
WO2019190192A1 (ko) | 신규한 프로모터 및 이를 이용한 l-아미노산 생산 방법 | |
WO2021167414A1 (ko) | 퓨린 뉴클레오티드를 생산하는 미생물 및 이를 이용한 퓨린 뉴클레오티드의 생산방법 | |
WO2019135639A1 (ko) | 신규 폴리펩타이드 및 이를 이용한 imp 생산방법 | |
WO2017069578A1 (ko) | L-이소루신 생산능을 가지는 코리네박테리움 속 미생물 및 이를 이용하여 l-이소루신을 생산하는 방법 | |
WO2021085999A1 (ko) | 외래 metZ 유전자에 의해 코딩되는 단백질이 도입된 L-메티오닌 생산 미생물 및 이를 이용한 L-메티오닌 생산방법 | |
WO2022055094A1 (ko) | L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 | |
WO2019004779A2 (ko) | 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법 | |
WO2019013569A1 (ko) | 활성형 d-프롤린 리덕타제를 발현하는 미생물 및 활성형 d-프롤린 리덕타제를 생산하는 방법 | |
WO2018230977A1 (ko) | 신규 폴리펩타이드 및 이를 이용한 오르니틴계 산물 생산방법 | |
WO2019013532A2 (ko) | 아세토하이드록시산 신타아제 변이체, 이를 포함하는 미생물 또는 이를 이용하는 l-분지쇄 아미노산 생산 방법 | |
WO2021060696A1 (ko) | 디하이드로디피콜린산 리덕타제 변이형 폴리펩티드 및 이를 이용한 l-쓰레오닌 생산방법 | |
WO2016013844A1 (ko) | 페닐아세틸 호모세린 락톤 유도체의 생산 방법 | |
WO2022124708A1 (ko) | 신규한 분지 연쇄 아미노산 아미노트렌스퍼라아제 변이체 및 이를 이용한 이소류신 생산 방법 | |
WO2019004780A2 (ko) | 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법 | |
WO2022050671A1 (ko) | L-발린 생산 미생물 및 이를 이용한 l-발린 생산 방법 | |
WO2021261733A1 (ko) | L-쓰레오닌 디하이드라타아제의 신규 변이체 및 이를 이용한 l-이소류신 생산 방법 | |
WO2022191630A1 (ko) | 신규한 시트레이트 신타아제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022164118A1 (ko) | 프리페네이트 탈수 효소 변이체 및 이를 이용한 분지쇄 아미노산 생산 방법 | |
WO2015060649A1 (ko) | O-숙시닐호모세린 생산 미생물 및 이를 이용한 o-숙시닐호모세린의 생산방법 | |
WO2022163904A1 (ko) | 신규한 단백질 변이체 및 이를 이용한 l-라이신 생산 방법 | |
WO2021153866A1 (ko) | 시트레이트 신타아제의 활성이 약화된 신규한 변이형 폴리펩티드 및 이를 이용한 l-아미노산 생산 방법 | |
WO2021060701A1 (ko) | 메조 디아미노피멜레이트 디하이드로게네이즈 변이형 폴리펩타이드 및 이를 이용한 l-쓰레오닌 생산방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18832792 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020520419 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020000525 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018832792 Country of ref document: EP Effective date: 20200212 |
|
ENP | Entry into the national phase |
Ref document number: 112020000525 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200109 |